Patent protections on the drug itself along with additional patents covering formulation and injection devicescontinue to delay competition
Your period might get a little weird after GLP-1s, especially if youve lost weight quickly or werent ovulating regularly to begin with
This decision is highly personal and should be made in partnership with a qualified bariatric care team that considers: Medical history Insurance eligibility Weight loss goals Long-term health outcomes What Patients in California Should Consider Next If you are currently usingor consideringGLP-1 medications and are concerned about insurance coverage, cost, or long-term sustainability, it may be time to explore all evidence-based weight loss options
It can be a huge psychological shock to go from feeling like a healthy, active person to reading that you might be at risk for a serious cardiac event
Surprisingly, alopecia was not identified in the 2018 randomized controlled trial with semaglutide, nor was alopecia a side effect of the 2021 RCT with terzepatide
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown superior efficacy in glycemic control, weight loss and cardiometabolic outcomes compared to GLP-1 agonists alone
